Vir Biotechnology Announces Collaboration Agreement with GSK
Monday, February 13, 2023
Vir Biotechnology announced that its 2020 research collaboration agreement with GSK is amended to reflect that Vir will continue its ongoing efforts to discover, develop and advance next-generation solutions for COVID-19 and other potential coronavirus epidemics, independently or with other partners.
The companies will continue to work together to ensure continued availability of sotovirumab to patients around the world, post-licencing, and to develop new therapies for influenza and other respiratory diseases.
Under the terms of the new amended agreement, Vir retains the sole rights to continue advancing next-generation solutions arising from the collaborative coronavirus vaccine and antibody programmes, subject to tiered low- to mid-single digit royalties to GSK. The Companies continue to collaborate on sotrovimab and VIR-7832, as well as a portfolio of other respiratory disease programmes.
In April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration used Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies developed as therapeutic or preventive options to help address the COVID-19 pandemic and future outbreaks. In 2021, the Companies expanded the collaboration to include the research and development of new therapies for influenza and other respiratory viruses.
